Compare ARK Genomic Revolution ETF (ARKG) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Tilray Brands Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Tilray Brands Inc trades at $4.46 (market cap $544.44M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | TLRY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $21.00 |
52-Week Low | $23.09 | $4.31 |
Market Cap | — | $544.44M |
Enterprise Value | — | $641.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
TLRY trades at $4.42, up 0.68% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows low valuation ratios (P/S 0.55, P/B 0.35) but deep losses (net margin -156.67%) and negative cash flow from operations. Recent news highlights expansion in medical cannabis and new product launches, yet earnings misses and high debt-to-asset ratios signal ongoing challenges.
Outlook remains uncertain with profitability elusive; growth via acquisitions adds scale but not earnings. Analyst consensus is cautious (25% buy, 65% hold), reflecting skepticism about near-term turnaround. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles in the cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
